Table 18: Patient characteristics in prognosis studies.
| Author, Year | Patient Characteristics by Group [R = Revascularization Group; MT = Medical Therapy Group] |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Mean Age (Range) | % Male | LVEF(%) | Previous MI (%) | Hypertension (%) | Diabetes (%) | 3 vessel CAD (%) | |||||||||
| R | MT | R | MT | R | MT | R | MT | R | MT | R | MT | R | MT | R | MT | |
| Desideri et al., 2005 (52) | 94 | 167 | 66 (58–70) |
66 (57–69) |
89 | 89 | 30 | 29 | 79 | 82 | 50 | 50 | 12 | 10 | NR | 47 |
| Feola et al., 2008 (53) | 51 | 42 | 65.7±9.1 | 62.6±9 | 76 | 30.8 ± 7.1 | 29.7 ± 7.7 | 100 | 100 | 65 | 29 | 31 | 35 | |||
| Sawada et al., 2005 (54) | 33 | 28 | 58±9 | 84 | 29±11 | NR | NR | NR | NR | 100 | 100 | NR | 78 | |||
| Rohatgi et al., 2001 (55) | 37 | 62 | V: 63±10 NV: 58±10 | V: 61±12 NV: 58±12 | 84 | 79 | 22±6 | V: 86 NV: 76 | V: 63 NV: 67 | NR | NR | V: 52 NV: 50 | V: 41 NV: 33 | NR | NR | |
| Zhang et al., 2001 (56) | 67 | 56 | V: 53±10 NV: 56±7 | V: 56±9 NV: 56±9 | V: 83 NV: 92 | V: 93 NV: 92 | V: 36±5 NV: 36±6 | V: 35±8 NV:34±6 | 100 | 100 | V: 50 NV: 48 | V: 40 NV: 27 | V: 19 NV: 12 | V: 7 NV: 12 | 55 | |
| Di Carli et al., 1998 (57) | 43 | 50 | median, 68 | Median, 69 | 88 | 80 | 25 | 25 | 72 | 64 | 26 | 12 | 16 | 10 | 37 | 24 |
| vom Dahl et al., 1997 (58)* | 84 | 77 | V: 57±9 NV (scar): 59±7 NV (mild match): 55±9 | V: 55±8 NV (scar): 58±9 NV (mild match): 55±9 | V: 89 NV: 94 | V: 89 NV: 87 | V: 49±10 NV (scar): 41±12 NV (mild match): 47±10 | V: 50±14 NV (scar): 44±13 NV (mild match): 48±1 | 88 | NR | NR | NR | NR | V: 45 NV: 52 | V: 56 NV: 25 | |
| Lee et al., 1994 (59) | 68 | 61 | V: 60±11 NV: 64±9 | V: 62±12 NV: 62±12 | 79 | V: 37±17 NV: 34±12 | V: 39±18 NV: 38±17 | 100 | 100 | NR | NR | NR | NR | V:82‡ NV: 89‡ | V:62‡ NV: | |
| Eitzman et al., 1992 (60) | 40 | 42 | V: 59±11 NV: 56±9 | V: 61±8 NV: 59±10 | 88 | V: 36±13 NV: 37±12 | V: 33±11 NV: 32±16 | NR | NR | NR | NR | NR | NR | NR | NR | |
R refers to revascularization group; MT, medical therapy group; FDG, F-18-fluorodeoxyglucose; LVEF, left ventricular ejection fraction; meds, medical therapy; NV, not viable myocardium; Rb, rubidium; revasc., revascularization; V, viable myocardium
*
In vom Dahl et al. (58), patients with non-viable myocardium were classified as either scar (marked reduction of technetium ≤ 50% without evidence for a mismatch, FDG minus technetium ≤ 20%) or mild match (mild reduction of technetium uptake of 51% to 70% without evidence for a mismatch, FDG minus technetium ≤ 20%).
‡
Percentage of patients with multi-vessel disease.